Percheron Therapeutics (ASX: PER; OTC: PERCF) has secured a potential international nonproprietary name (pINN) from the World Health Organization (WHO) for its investigational cancer therapy HMBD-002.
According to Percheron, the WHO has selected the name minperstobart for the therapy, which will gradually begin appearing in clinical trial protocols, scientific publications, and other communications ahead of formal confirmation expected in 2027.
In a statement, Dr. James Garner, managing director and CEO of Percheron, commented, “The selection of an INN is always a key waypoint as drug candidates progress towards commercialisation. Since we in-licenced HMBD-002 some 10 months ago, the team has been working hard to prepare the drug for the next stage of development. Applying for an INN has been one of those many activities, and we are pleased to see that specific piece of work now successfully completed.”
